E
REGENXBIO Inc. RGNX
$6.72 $0.172.60%
Recommendation
Sell
Prev Close
$6.55
Volume
1,600,595
Avg Vol (90D)
1,140,960
Market Cap
$324.52M
Dividend & Yield
--
52-Week Range
$5.62 - $23.14
P/E (TTM)
--
EPS (TTM)
-$5.04
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Fair
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
REGENXBIO (RGNX, $6.72) Stochastic Oscillator left the overbought zone on March 14, 2025
3/15/2025 - Tickeron - Stocks
REGENXBIO (NASDAQ:RGNX) Posts Quarterly Earnings Results, Beats Estimates By $0.26 EPS
3/14/2025 - MarketBeat
Stifel Nicolaus Keeps Their Buy Rating on RegenXBio (RGNX)
3/14/2025 - TipRanks Financial Blog
Regenxbio price target raised by $2 at Morgan Stanley, here's why
3/14/2025 - The Fly
REGENXBIO (RGNX, $6.55) Aroon Indicator entered a Downtrend on March 13, 2025.
3/14/2025 - Tickeron - Stocks
Regenxbio Inc (RGNX) Q4 2024 Earnings Call Highlights: Strategic Advances and Financial Resilience
3/14/2025 - GuruFocus
Q4 2024 Regenxbio Inc Earnings Call Transcript
3/14/2025 - GuruFocus
REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript
3/13/2025 - SeekingAlpha
REGENXBIO Inc. (RGNX) Q4 2024 Earnings Call Transcript
3/13/2025 - Seeking Alpha: Transcripts
Regenxbio Inc (RGNX) Q4 2024 Earnings: EPS Beats Estimates at -$1.01, Revenue Misses at $21. ...
3/13/2025 - GuruFocus
Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates
3/13/2025 - Zacks Investment Research
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
3/13/2025 - GuruFocus
Regenxbio reports Q4 EPS ($1.01), consensus ($1.08)
3/13/2025 - The Fly
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Operational Updates
3/13/2025 - PR Newswire
REGENXBIO (RGNX, $6.67) Moving Average Convergence Divergence (MACD) Histogram turned positive on March 12, 2025
3/13/2025 - Tickeron - Stocks
REGENXBIO (RGNX, $6.67) Aroon Indicator entered a Downtrend on March 12, 2025.
3/13/2025 - Tickeron - Stocks
REGENXBIO (RGNX, $6.11) Aroon Indicator entered a Downtrend on March 11, 2025.
3/12/2025 - Tickeron - Stocks
REGENXBIO (RGNX, $6.01) Aroon Indicator entered a Downtrend on March 10, 2025.
3/11/2025 - Tickeron - Stocks
REGENXBIO (RGNX, $6.01) Aroon Indicator entered a Downtrend on March 10, 2025.
3/11/2025 - Tickeron - Stocks
REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical ...
3/10/2025 - GuruFocus
REGENXBIO Announces Presentations at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
3/10/2025 - PR Newswire
REGENXBIO (RGNX, $6.34) Aroon Indicator entered a Downtrend on March 07, 2025.
3/8/2025 - Tickeron - Stocks
REGENXBIO Inc. (NASDAQ:RGNX) Shares Sold by Rhumbline Advisers
3/8/2025 - MarketBeat
REGENXBIO (NASDAQ:RGNX) Upgraded by StockNews.com to Hold Rating
3/7/2025 - MarketBeat
REGENXBIO (RGNX, $6.25) RSI Indicator left the oversold zone on March 05, 2025
3/6/2025 - Tickeron - Stocks
Income Statement
Total Revenue (TTM)
$84.33M
EBITDA (TTM)
-$223.55M
EBIT (TTM)
-$240.08M
Net Income (TTM)
-$238.81M
Balance Sheet
Total Assets (Q)
$519.11M
Total Debt (Q)
$145.81M
Total Liabilities (Q)
$217.70M
Book Value Per Share (Q)
$6.09
Cash Flow
Cash from Operations (TTM)
-$182.26M
Cash from Investing (TTM)
$97.15M
Cash from Financing (TTM)
$88.46M
Net Change in Cash (TTM)
$3.35M
Filings
Filing Date
Wednesday, November 6, 2024
Period Date
Monday, September 30, 2024
Next Filing
Week of Feb 24 and 28 (est)
Price History
Loading...
Beta
1.72
7-Day Total Return
7.52%
30-Day Total Return
-14.94%
60-Day Total Return
-18.84%
90-Day Total Return
-21.77%
Year to Date Total Return
-14.50%
1-Year Total Return
-69.24%
2-Year Total Return
-68.05%
3-Year Total Return
-74.21%
5-Year Total Return
-73.47%
52-week Low
Mar 04, 2025 - $5.62
52-week High
Mar 21, 2024 - $23.14
Valuation
Market Cap
$324.52M - Small Cap
Enterprise Value
$221.37M
Price/Sales (TTM)
3.95
Price/Book (Q)
1.08
Dividends and Shares
Shares Outstanding
50.80M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.regenxbio.com
Phone Number
240 552 8181
Address
9804 Medical Center Drive
Rockville, MD 20850
Country
United States
Year Founded
2008
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product... more
NASDAQ 03/14/2025 4:00PM Eastern Quotes delayed
Weiss Ratings